Document Type: Research Articles
Department of Clinical Biochemistry, Faculty of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.
Pistachio Safety Research Center, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.
Molecular Medicine Research Center, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.
Research Center of Advanced Technologies in Medicine, Torbat Heydariyeh University of Medical Sciences, Torbat Heydariyeh, Iran.
Department of Clinical Biochemistry, Afzalipoor Faculty of Medicine, Kerman University of Medical Sciences, Kerman, Iran.
Objectives: In the present study, we aimed to identify the anti-proliferative potential of [Cu(L)(2imi)] complex
[L = 2-(((5-chloro-2-oxyphenyl)imino)methyl)phenolato) and 2imi = 2-methyl imidazole] against HepG2 cells as an
in vitro model of human hepatocellular carcinoma and normal mouse fibroblast L929 cells. Methods: The cytotoxic
and apoptotic effects of [Cu(L)(2imi)] complex on HepG2 cells and normal fibroblasts (L929) were examined by MTT
assay and flow cytometry, respectively. Results: Cytotoxicity induced by [Cu(L)(2imi)] complex was time dependent.
Also, there was a positive correlation between cytotoxicity and an increase in Cu complex concentration. For HepG2
cells, the cell viability percentage was 50% at 58 μg/mL after 24 h treatment, whereas in the same concentration and
conditions, the viability percentage was surprisingly higher (about 100%) for L929 cells. Also, after 48 h treatment,
the viability percentage of HepG2 cells at 55 μg/mL concentration was 50% in contrast with 89.3% for L929 cells in
the same conditions. Flow cytometry findings suggest that [Cu(L)(2imi)] complex is capable of decreasing cancer cell
viability through apoptosis and did not efficiently activate the necrosis process. Conclusions: Finally, we found that
[Cu(L)(2imi)] complex possess the potential for development as an anti-cancer drug for human hepatocellular carcinoma.